 |
 |
外科學(xué)論文:原發(fā)性骨質(zhì)疏松癥治療藥物及療效隨訪原則
關(guān)鍵詞 原發(fā)性骨質(zhì)疏松癥 診治指南 藥物治療
中圖分類號(hào)：R977 文獻(xiàn)標(biāo)識(shí)碼：C 文章編號(hào)：1006-1533（2013)09-0001-05
Drugs in the treatment of primary
osteoporosis and the following-up principles of their efficacy
Zhang Zhenlin
（Metabolic Bone Disease and Genetic Research Unit， Department of Osteoporosis and Bone Disease，
Sixth People’s Hospital， Shanghai Jiao Tong University， Shanghai 200233， China)
ABSTRACT According to the updated Guidelines for the Diagnosis and Treatment of Primary Osteoporosis written mainly by the Panch of Osteoporosis and Bone Mineral Diseases of the Chinese Medical Society， this article introduces the drugs in the treatment of primary osteoporosis and the following-up principles of their efficacy so as to help the clinical doctors standardize the application of the drugs to prevent and treat osteoporosis.
Key Words primary osteoporosis； guideline for the diagnosis and treatment； pharmaceutical treatment
骨質(zhì)疏松癥是一種因骨量低下、骨微結(jié)構(gòu)破壞而致骨脆性增加并易發(fā)生骨折的全身性骨病，常見于絕經(jīng)后婦女和老年男性。骨質(zhì)疏松癥分為原發(fā)性和繼發(fā)性兩類。原發(fā)性骨質(zhì)疏松癥又可再分為絕經(jīng)后骨質(zhì)疏松癥、老年性骨質(zhì)疏松癥和特發(fā)性骨質(zhì)疏松癥。本文主要依據(jù)中華醫(yī)學(xué)會(huì)骨質(zhì)疏松和骨礦鹽疾病分會(huì)2011年發(fā)布的新版《原發(fā)性骨質(zhì)疏松診治指南》[1]，就原發(fā)性骨質(zhì)疏松癥治療藥物及療效隨訪原則進(jìn)行介紹，以期幫助臨床醫(yī)生規(guī)范應(yīng)用骨質(zhì)疏松癥防治藥物醫(yī).學(xué)全.在.線網(wǎng)站payment-defi.com。
1 防治目的
骨質(zhì)疏松癥初級(jí)預(yù)防是指對(duì)尚無骨質(zhì)疏松、但具有骨質(zhì)疏松癥危險(xiǎn)因素者應(yīng)防止或延緩其發(fā)展為骨質(zhì)疏松癥并避免發(fā)生第1次骨折；骨質(zhì)疏松癥二級(jí)預(yù)防是指對(duì)已患骨質(zhì)疏松癥或T值≤-2.5、或已發(fā)生過脆性骨折者的防治目的是避免發(fā)生或再次發(fā)生骨折。
2 應(yīng)用藥物
完整的骨質(zhì)疏松癥防治策略包括基礎(chǔ)措施、藥物干預(yù)和康復(fù)治療。本文主要介紹藥物干預(yù)部分。
